Clinical trials
Recurrence trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
118 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 4 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 10 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 12 |
| 2022 | 8 |
| 2023 | 9 |
| 2024 | 11 |
| 2025 | 10 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 47 |
| Recruiting | 23 |
| Active, not recruiting | 22 |
| Terminated | 19 |
| Not yet recruiting | 3 |
| Unknown status | 2 |
| Withdrawn | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 12 |
| Novartis Pharmaceuticals | 11 |
| Pfizer | 11 |
| AstraZeneca | 6 |
| AbbVie | 5 |
| Bristol-Myers Squibb | 5 |
| Alexion Pharmaceuticals, Inc. | 4 |
| Amgen | 4 |
| Genmab | 4 |
| Eisai Co., Ltd. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 118 |
| Multiple Myeloma | 30 |
| Lymphoma, Large B-Cell, Diffuse | 13 |
| Neoplasms | 13 |
| Lymphoma, Non-Hodgkin | 11 |
| Lymphoma, Follicular | 9 |
| Lymphoma | 8 |
| Lymphoma, B-Cell | 7 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 |
| Neoplasm Metastasis | 6 |
Trials
Showing 26 to 50 of 118. Each trial links to its page on Pharma Observatory.
18 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.